Oral VK2735 demonstrated early, progressive weight loss from Week 1 through Week 13 without a plateau

Dose-dependent weight loss observed across all VK2735 cohorts, with the highest dose achieving a mean reduction of up to 12.2% (26.6 lbs) from baseline at Week 13

Baseline characteristics in the ongoing Phase 3 VANQUISH-1 study of VK2735 in adults with obesity were also presented in a second poster at the conference

SAN DIEGO, May 12, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today presented additional data from its Phase 2 VENTURE-Oral Dosing trial evaluating the oral tablet formulation of VK2735 at the European Congress on Obesity (ECO) in Istanbul, Türkiye. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development with subcutaneous and oral formulations for the potential treatment of various metabolic disorders.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.